Disclosed are granulocyte-macrophage colony stimulating factor (GM-CSF) variants, polynucleotides encoding the GM-CSF variants, and methods of making and using the GM-CSF variants for the treatment of immune-related disorders, such as inflammatory bowel disease (IBD). Further disclosed are amino acid sequences of the GM-CSF variants and the nucleotide sequences encoding the GM- CSF variants.
